Claghorn-Lesem Research Clinic, Ltd. operates under the rigorous standards promulgated by ICH and GCP guidelines as directed and regulated by the FDA. To insure our compliance and facilitate our ongoing staff training programs, we engaged a former FDA auditor to write and implement a set of SOP's specific to our facilities and operations. These stringent internal operational controls in combination with our routine self-auditing have supported us through various Sponsor and FDA audits.

  Psychotic Disorders

• Acute schizophrenia
• Treatment resistant schizophrenia
• Long term maintenance in schizophrenia
• Relapse prevention in schizophrenia
• Cognition in schizophrenia / P-50 gating
• QTc comparison trials in schizophrenia
• Intramuscular dosing with atypical agents in psychosis with acute agitation
• Combination antipsychotic therapy with mood stabilizers in schizophrenia
• Bioequivalence in schizophrenia studies
• Depot formulations of atypical antipsychotics in schizophrenia
• Schizophrenia with prominent negative symptoms

Affective Disorders

• Major depression
• Melancholic depression
• Treatment resistant depression
• Prevention of relapse in depression
• Geriatric depression
• Psychotic depression
• Bipolar depression
• Bipolar mania
• Treatment resistant bipolar mania
• Combination antipsychotic therapy with mood stabilizers in mania
• Bipolar mixed episode

Dementia / Cognitive Disorders

• Dementia with psychosis
• Alzheimer's

Anxiety Disorders

• Generalized Anxiety Disorder
• PTSD
• Social anxiety
• Social phobia
• OCD

 Childhood Disorders

• ADHD
• Pharmacokinetics in children and adolescents
• ODD in children and adolescents
• Conduct disorder in mentally retarded children
• Adolescent schizophrenia
• Bipolar disorder in children and adolescents
• Depression in children and adolescents

Additional Experience

• Migraine
• PMS
• Insomnia
• Insomnia in the elderly
• Pharmacogenomic sampling
• Erectile dysfunction